Related Experiment Videos
ET-743: more than an innovative mechanism of action
1Department of Pharmacology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA. KW_Scotto@fccc.edu
Abstract:
Ecteinascidin-743 (ET-743), an anti-tumor agent derived from the marine tunicate, Ecteinascidia turbinata, is active against various solid tumor cell lines, including soft tissue sarcoma, breast, ovarian, non-small-cell lung and prostate cancers and melanoma, and has a broad spectrum of anti-cancer activity in vivo. For reasons as yet unclear, sarcoma cell lines are exquisitely sensitive to ET-743. The drug has a unique mechanism of action that makes it a novel anti-tumor agent. ET-743 is a DNA-binding agent that covalently interacts with the minor groove of the DNA double helix to bend the molecule towards the major groove. Defects in DNA repair pathways have paradoxical effects on the anti-tumor activity of ET-743: loss of mismatch repair does not affect its toxicity; loss of DNA-dependent protein kinase activity enhances its toxicity; defects in transcription-coupled nucleotide excision repair confer resistance to ET-743. As a DNA repair capability appears to be necessary for at least one mechanism of ET-743-mediated cytotoxicity, the drug may interact with the DNA repair machinery to induce lethal strand breaks. One of the most novel aspects of ET-743 is its effect on RNA polymerase II-mediated gene transcription. ET-743 selectively inhibits activation of the multidrug resistance gene, while leaving constitutive gene expression relatively unaffected. Preliminary studies of other genes and transcriptional inducers indicate that ET-743 may be a more general inhibitor of activated, but not basal, transcription.
Insights
Ecteinascidin-743 (ET-743), a marine-derived anti-tumor drug, shows broad activity against solid tumors. Its unique DNA-binding mechanism and selective inhibition of activated gene transcription offer novel anti-cancer potential.
Area of Science:
- Pharmacology
- Molecular Biology
- Oncology
Background:
- Ecteinascidin-743 (ET-743) is a potent anti-tumor agent derived from the marine tunicate Ecteinascidia turbinata.
- ET-743 exhibits broad anti-cancer activity against various solid tumors, including sarcomas, breast, ovarian, lung, prostate cancers, and melanoma, both in vitro and in vivo.
- Sarcoma cell lines demonstrate exceptional sensitivity to ET-743, though the underlying reasons remain unclear.
Purpose of the Study:
- To elucidate the unique mechanism of action of ET-743 as a novel anti-tumor agent.
- To investigate the interaction of ET-743 with DNA and its effects on DNA repair pathways.
- To examine the impact of ET-743 on RNA polymerase II-mediated gene transcription, particularly its selective inhibition of activated gene expression.
Main Methods:
- The study involved analyzing the DNA-binding properties of ET-743, focusing on its covalent interaction with the minor groove of DNA.
- Investigated the effects of defects in various DNA repair pathways (mismatch repair, DNA-dependent protein kinase activity, transcription-coupled nucleotide excision repair) on ET-743 toxicity and resistance.
- Examined the influence of ET-743 on RNA polymerase II-mediated transcription, including its effect on the multidrug resistance gene and other activated genes.
Main Results:
- ET-743 functions as a DNA-binding agent, inducing a bend in the DNA double helix.
- DNA repair pathway defects exhibit paradoxical effects: loss of mismatch repair has no impact, loss of DNA-dependent protein kinase enhances toxicity, and defects in transcription-coupled nucleotide excision repair confer resistance.
- ET-743 selectively inhibits the activation of genes, such as the multidrug resistance gene, while largely sparing basal transcription.
Conclusions:
- ET-743's anti-tumor activity is linked to its DNA-binding capacity and interaction with the DNA repair machinery, potentially inducing lethal strand breaks.
- The drug's ability to selectively inhibit activated transcription, rather than basal transcription, represents a novel anti-cancer mechanism.
- ET-743 holds significant promise as a novel therapeutic agent for various solid tumors, particularly those with specific DNA repair or transcriptional vulnerabilities.